OKYO Stock Forecast & Price Target

OKYO Pharma Ltd has shown promising advancements in the clinical development of its therapeutic candidate, urcosimod, particularly with efficacy metrics indicating significant patient improvement. Notably, 67% of participants receiving the 0.05% concentration of urcosimod reported more than 50% pain reduction, a substantial increase over the 33% improvement noted in the placebo group, suggesting strong therapeutic potential. Furthermore, the early marked reduction in pain scores as soon as Week 4 enhances the credibility of the drug's effectiveness, fostering a positive outlook for the company’s future performance.

OKYO Pharma Ltd reported a net loss of $4.7 million, or $0.12 per share, for the fiscal year ending March 31, 2025, reflecting ongoing financial challenges. Key risks include the potential failure of its lead candidate, urcosimod, in clinical trials and its inability to obtain regulatory approval in the U.S., which could significantly impair future revenue prospects. Additionally, concerns regarding market size and competition, alongside potential dilution risk, further exacerbate the negative outlook for the company's stock performance.